A new mRNA treatment that temporarily activates Myc and Cyclin T1 reawakens mouse heart cells, boosting cardiac output by about 10% after a heart attack.
Posts tagged as “preclinical study”
Brigham Young University scientists say their MOTO‑CAR platform cut aggressive lung cancer cells by 90% in lab tests, highlighting a potential low‑cost immunotherapy route.
Researchers at Cedars‑Sinai identified the enzyme UBE2N as a natural defender against worsening fatty liver disease, offering a potential new target to prevent progression to MASH.


